Journal Article

Therapeutic potential of siRNA-mediated combined knockdown of the IAP genes (<i>Livin</i>, <i>XIAP</i>, and <i>Survivin</i>) on human bladder cancer T24 cells

Deyong Yang, Xishuang Song, Jianing Zhang, Lin Ye, Shujing Wang, Xiangyu Che, Jianbo Wang, Zhiwei Zhang, Lina Wang and Wei Shi

in Acta Biochimica et Biophysica Sinica

Published on behalf of Institute of Biochemistry and Cell Biology, SIBS, CAS

Volume 42, issue 2, pages 137-144
Published in print February 2010 | ISSN: 1672-9145
Published online February 2010 | e-ISSN: 1745-7270 | DOI: http://dx.doi.org/10.1093/abbs/gmp118
Therapeutic potential of siRNA-mediated combined knockdown of the IAP genes (Livin, XIAP, and Survivin) on human bladder cancer T24 cells

Show Summary Details

Preview

Livin, X-linked inhibitor of apoptosis (XIAP), and Survivin are three well-known inhibitors of apoptosis almost exclusively over-expressed in cancer cells and are considered potent targets for cancer treatment. In the present study, we found that Livin, XIAP, and Survivin were simultaneously expressed in bladder cancer cells. We speculated that Livin, XIAP, and Survivin might have synergistic effects on cell growth and apoptosis. Our results confirmed that combined knockdown of all these three genes can synergistically inhibit the proliferation and transformation ability of high-grade bladder cancer T24 cells and promote the cell apoptotic sensitivity to chemotherapy. Furthermore, combined knockdown of Livin, XIAP, and Survivin can markedly increase the abundance of active caspase-3, active caspase-7, active caspase-9, and cytosolic Smac. Our findings imply that combined silencing of Livin, XIAP, and Survivin may be a potent multi-targeted gene therapy for bladder cancer.

Keywords: Livin; XIAP; Survivin; bladder cancer; multi-targeted therapy

Journal Article.  4024 words.  Illustrated.

Subjects: Biochemistry

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.